Deep learning enables rapid identification of potent DDR1 kinase inhibitors; Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data; druGAN: an advanced generative adversarial autoencoder model for de novo generation of new molecules with desired molecular properties in silico; Converging blockchain and next-generation artificial intelligence technologies to decentralize and accelerate biomedical research and healthcare; The cornucopia of meaningful leads: Applying deep adversarial autoencoders for new molecule development in oncology; Deep biomarkers of human aging: application of deep neural networks to biomarker development; Potential 2019-nCoV 3C-like protease inhibitors designed using generative deep learning approaches; Entangled conditional adversarial autoencoder for de novo drug discovery; Adversarial Threshold Neural Computer for Molecular de Novo Design; Genetics and epigenetics of aging and longevity; DNA repair in species with extreme lifespan differences; Population specific biomarkers of human aging: a big data study using South Korean, Canadian, and Eastern European patient populations; Artificial intelligence for aging and longevity research: Recent advances and perspectives; Molecular aspects of development and regulation of endometriosis; Design of efficient computational workflows for in silico drug repurposing; A role for G‐CSF and GM‐CSF in nonmyeloid cancers; In silico Pathway Activation Network Decomposition Analysis (iPANDA) as a method for biomarker development; Geroprotectors. org: a new, structured and curated database of current therapeutic interventions in aging and age-related disease; Biohorology and biomarkers of aging: Current state-of-the-art, challenges and opportunities; Human-specific endogenous retroviral insert serves as an enhancer for the schizophrenia-linked gene PRODH
